C.R. Bard Director Sells $323,184 in Stock (BCR)
C.R. Bard (NYSE:BCR) Director Herbert Henkel unloaded 2,400 shares of the company’s stock on the open market in a transaction dated Monday, October 28th. The shares were sold at an average price of $134.66, for a total value of $323,184.00. Following the transaction, the director now directly owns 9,701 shares in the company, valued at approximately $1,306,337. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
C.R. Bard (NYSE:BCR) traded up 0.36% on Tuesday, hitting $135.58. 511,734 shares of the company’s stock traded hands. C.R. Bard has a 1-year low of $93.79 and a 1-year high of $119.99. The stock’s 50-day moving average is $115.6 and its 200-day moving average is $107.2. The company has a market cap of $10.732 billion and a price-to-earnings ratio of 74.56.
C.R. Bard (NYSE:BCR) last released its earnings data on Tuesday, October 22nd. The company reported $1.50 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.40 by $0.10. The company had revenue of $758.00 million for the quarter, compared to the consensus estimate of $739.12 million. During the same quarter last year, the company posted $1.64 earnings per share. C.R. Bard’s revenue was up 4.9% compared to the same quarter last year. Analysts expect that C.R. Bard will post $5.78 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Friday, November 1st. Stockholders of record on Monday, October 21st will be given a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 0.62%. The ex-dividend date of this dividend is Thursday, October 17th.
BCR has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of C.R. Bard in a research note to investors on Thursday, October 24th. They now have a $143.00 price target on the stock. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of C.R. Bard from $126.00 to $142.00 in a research note to investors on Wednesday, October 23rd. They now have an “overweight” rating on the stock. Finally, analysts at JMP Securities raised their price target on shares of C.R. Bard from $130.00 to $140.00 in a research note to investors on Wednesday, October 23rd. They now have a “market outperform” rating on the stock. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and six have issued a buy rating to the stock. C.R. Bard has an average rating of “Hold” and a consensus price target of $126.88.
C. R. Bard, Inc (NYSE:BCR) is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.